Clinical trial
A Phase I/IIa, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Relative Bioavailability and Food Effect Cohort to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of CYB003 in Healthy Participants With and Without Major Depressive Disorder (MDD)
NCT05385783 is registered in ClinicalTrials.gov with Cybin IRL Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I/IIa, Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Relative Bioavailability and Food Effect Cohort to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Oral Doses of CYB003 in Healthy Participants With and Without Major Depressive Disorder (MDD)
- Lead sponsor
- Cybin IRL Limited
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- August 2, 2022
- Completion date
- January 18, 2024
- Enrollment
- 57 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.